Page 3 - Expanded Use Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FDA indicated that approval of MAT2203 as a first-line treatment for invasive aspergillosis will require an adequately powered study with an active control group and an all-cause mortality.

United statesNew jerseyJody cainMatinas biopharmaJeromed jabbourNational resilience incNational resilienceDevelopment authorityAccess programEuropean congressMatina compassionate expanded use programDrug administrationPopulation pathway for antifungalsOral amphotericinb programKey program updatesMatinas biopharma holdings inc